Navigation Links
Thesan Pharmaceuticals Appoints Dr. Bhaskar Chaudhuri to the Board of Directors August 2014
Date:8/25/2014

SAN DIEGO, Aug. 25, 2014 /PRNewswire/ -- Thesan Pharmaceuticals announced today the appointment of Bhaskar Chaudhuri Ph.D., to its Board of Directors. Dr. Chaudhuri has more than 25 years of experience in pharmaceuticals management, drug research & development, and commercialization in the US, EU and emerging markets. He has led the development and FDA approval of multiple NDAs and ANDAs. Most recently, Dr. Chaudhuri served as President of Valeant Pharmaceuticals before becoming an Operating Partner at Frazier Healthcare. Prior to joining Valeant, Dr. Chaudhuri served as President and CEO of Dow Pharmaceuticals leading up to their acquisition by Valeant. Before Dow, Dr. Chaudhuri worked at Bertek Pharmaceuticals (a subsidiary of Mylan Laboratories) as Executive Vice President of Scientific Affairs and as the General Manager of the Dermatology Division of Mylan Laboratories. Dr. Chaudhuri holds a Doctorate in Physical Pharmacy. He also serves on the Board of multiple pharmaceutical companies.

"We are delighted to have Bhaskar join our Board at this time," said Gordon Foulkes, Thesan's CEO. "His superb track record of developing dermatology drugs, his commercialization expertise, and leadership role in the sale of multiple dermatology companies will be a tremendous help to Thesan going forward as we continue to build our Executive leadership team for the future."

"I am truly honored to be included as part of the Thesan team," Dr. Chaudhuri added. "The current portfolio of breakthrough products managed by a world class team gives Thesan the foundation to be a preeminent Dermatology company. I look forward to contributing towards the growth of Thesan and be part of a leading Dermatology organization."

Also at this time, in connection with the recent Series B financing, Dr. Peter Moldt of Novo Ventures will become the new Novo Board member to represent their investment in Thesan. Dr. Moldt has had extensive experience in the biotechnology industry, serving either as CEO, COO or head of R&D in a number of successful companies, including Curalogic A/S, which he founded and then took public in 2006. Dr. Moldt joined Novo Ventures in 2009.

About Thesan Pharmaceuticals, Inc.

Thesan is a biotechnology company focused on the development and commercialization of novel drugs for the treatment of dermatological conditions.
For more information visit: www.thesanpharma.com

Contact:
J. Gordon Foulkes, Ph.D.
Chief Executive Officer
Thesan Pharmaceuticals, Inc.
Info@ThesanPharma.com


'/>"/>
SOURCE Thesan Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Thesan Pharmaceuticals udpeger Dr. Bhaskar Chaudhuri til bestyrelsen i august 2014
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
4. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
5. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
7. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
8. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
9. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
10. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
11. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... 2016 , ... After several promising treatments in Panama using ... of Knowledge in Panama, a 6 year-old Duchenne’s muscular dystrophy patient received his ... following FDA approval of a second application for a single patient, investigational new ...
(Date:5/26/2016)... ... May 26, 2016 , ... FireflySci has ... in leading laboratories all over the globe. Their cute firefly logo has been ... awesome cuvettes, FireflySci makes spectrophotometer calibration standards that never require recalibration. These ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... delegation at BIO 2016 in San Francisco. Located at booth number 7301, representatives ... to answer questions and discuss the Thai biotechnology and life sciences sector. ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... recently became double board-certified in surgery and surgery of the hand by the ... is no stranger to going above and beyond in his pursuit of providing ...
Breaking Biology Technology:
(Date:3/10/2016)... , March 10, 2016 ... new market research report "Identity and Access Management Market ... Audit, Compliance, and Governance), by Organization Size, by Deployment, ... 2020", published by MarketsandMarkets, The market is estimated to ... 12.78 Billion by 2020, at a Compound Annual Growth ...
(Date:3/9/2016)... March 9, 2016 This BCC Research report ... of the RNA Sequencing (RNA Seq) market for the ... instruments, tools and reagents, data analysis, and services. ... of the RNA-Sequencing market such as RNA-Sequencing tools and ... main factors affecting each segment and forecast their market ...
(Date:3/9/2016)... , March 9, 2016  Crossmatch ® , ... enrollment solutions, today announced the addition of smart ... Altus multi-factor authentication platform. New contextual and ... to step-up security where it,s needed most — ... Washington, DC . --> ...
Breaking Biology News(10 mins):